Cargando…

AGREE-II Appraisal of a clinical algorithm for hypotonia assessment

OBJECTIVE: The objective of this study was to systematically appraise the quality of an evidenced-based clinical algorithm for the clinical assessment of hypotonia in children. DESIGN: The Appraisal of Guidelines for Research and Evaluation (AGREE) II tool with 23 items and six domains was used. The...

Descripción completa

Detalles Bibliográficos
Autor principal: Govender, Pragashnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Makerere Medical School 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307006/
https://www.ncbi.nlm.nih.gov/pubmed/30603013
http://dx.doi.org/10.4314/ahs.v18i3.38
Descripción
Sumario:OBJECTIVE: The objective of this study was to systematically appraise the quality of an evidenced-based clinical algorithm for the clinical assessment of hypotonia in children. DESIGN: The Appraisal of Guidelines for Research and Evaluation (AGREE) II tool with 23 items and six domains was used. The study was located in South Africa. Ten appraisers, who were recruited based on specific selection criteria, completed the assessment. RESULTS: Nine appraisers recommended the EBCA without any modification. Scope and purpose (94%), stakeholder involvement (91%) and editorial independence (99%) were rated the highest with the lower scoring domains being clarity of presentation (85%) and applicability (86%) due to clarity required in areas of resource implications and auditing and monitoring criteria. Inter-rater reliability was strong (ICC 0.7) amongst the appraisers in this study. CONCLUSION: This is the first independent assessment of the methodological rigour and transparency of a clinical algorithm using the AGREE-II instrument. Determining the quality of the EBCA for practice is essential as this would ultimately aid clinicians towards more accurate clinical assessment of hypotonia which would inevitably impact outcomes and management of the child presenting with this symptom. Whilst the AGREE-II provided initial feedback on the methodological rigour of development, understanding that the AGREE-II instrument evaluates the guideline development process and not the content is also essential in order to consider the next stage which would be to consider clinicians feedback on the clinical utility of this EBCA.